Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
34.26
-0.69 (-1.97%)
At close: Apr 10, 2026, 4:00 PM EDT
34.46
+0.20 (0.59%)
After-hours: Apr 10, 2026, 7:53 PM EDT

Viking Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
48.3949.2837.0216.1210.7
Research & Development
344.96101.6463.8154.2344.98
Total Operating Expenses
393.34150.92100.8370.3655.68
Operating Income
-393.34-150.92-100.83-70.36-55.68
Total Non-Operating Income (Expense)
33.740.9614.931.490.69
Pretax Income
-359.64-109.96-85.9-68.87-54.99
Net Income
-359.64-109.96-85.9-68.87-54.99
Net Income to Common
-359.64-109.96-85.9-68.87-54.99
Shares Outstanding (Basic)
113109947777
Shares Outstanding (Diluted)
113109947777
Shares Change (YoY)
3.33%15.57%22.79%-0.47%6.34%
EPS (Basic)
-3.19-1.01-0.91-0.90-0.71
EPS (Diluted)
-3.19-1.01-0.91-0.90-0.71
Shares Outstanding
114.79111.5797.9278.2678.25
Free Cash Flow
-278.69-87.79-73.38-48.4-47.59
Free Cash Flow Per Share
-2.47-0.81-0.78-0.63-0.62
EBITDA
-392.91-150.58-100.54-70.06-55.39
EBIT
-393.34-150.92-100.83-70.36-55.68
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q